Recent developments have elevated Kyle Diamantas to the forefront of trader expectations for Trump's FDA commissioner announcement. Makary's resignation in mid-May created an immediate vacancy, prompting the president to designate Diamantas, then deputy commissioner for food, as acting head via public statement. This internal elevation, combined with his established liaison role across HHS and the White House, has driven the 52.5% market share, while other named candidates remain distant due to lack of comparable recent signals. The 18.9% probability attached to no announcement by year-end accounts for the deliberate pace of Senate-confirmed appointments and the administration's reported review of multiple profiles aligned with regulatory priorities.